HCL Technologies Limited (NSE:HCLTECH)

Revance Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	994	964	1,134	1,103	1,387	892
Short-Term Investments	2,118	2,030	1,701	1,127	780	1,109
Trading Asset Securities	94	370	426	217	324	140
Cash & Short-Term Investments	3,206	3,364	3,261	2,447	2,491	2,141
Cash Growth	1.88%	3.16%	33.27%	-1.77%	16.35%	34.24%
Accounts Receivable	3,269	3,170	3,228	3,179	2,895	2,594
Other Receivables	151	114	74	24	81	108
Receivables	3,420	3,284	3,302	3,203	2,976	2,702
Inventory	18	16	22	28	21	13
Prepaid Expenses	288	283	218	200	195	175
Other Current Assets	332	318	312	642	657	859
Total Current Assets	7,264	7,265	7,115	6,520	6,340	5,890
Property, Plant & Equipment	908	887	949	943	1,062	1,144
Long-Term Investments	74	83	11	14	15	13
Goodwill	2,598	2,545	2,415	2,260	2,299	2,351
Other Intangible Assets	759	807	856	1,016	1,286	1,628
Long-Term Accounts Receivable	279	286	163	83	242	312
Long-Term Deferred Tax Assets	128	125	124	152	155	161
Long-Term Deferred Charges	119	128	162	189	223	191
Other Long-Term Assets	154	222	172	193	127	99
Total Assets	12,283	12,348	11,967	11,370	11,749	11,789
Accounts Payable	330	353	308	307	303	237
Accrued Expenses	626	838	730	643	631	583
Current Portion of Long-Term Debt	260	260	13	17	8	11
Current Portion of Leases	195	158	131	106	92	95
Current Income Taxes Payable	400	329	277	262	178	175
Current Unearned Revenue	1,026	978	918	995	1,005	963
Other Current Liabilities	372	365	349	278	261	315
Total Current Liabilities	3,209	3,281	2,726	2,608	2,478	2,379
Long-Term Debt	8	8	267	257	518	523
Long-Term Leases	302	309	281	202	219	260
Long-Term Unearned Revenue	113	124	126	95	87	70
Long-Term Deferred Tax Liabilities	191	189	93	20	15	20
Other Long-Term Liabilities	170	159	181	135	140	137
Total Liabilities	4,125	4,198	3,781	3,409	3,567	3,571
Common Stock	72	72	72	72	72	72
Additional Paid-In Capital	1	1	1	1	1	1
Retained Earnings	7,666	7,821	7,802	7,763	7,700	7,586
Treasury Stock	-88	-94	-96	-106	-106	-
Comprehensive Income & Other	505	348	406	232	503	537
Total Common Equity	8,156	8,148	8,185	7,962	8,170	8,196
Minority Interest	2	2	1	-1	12	22
Shareholders' Equity	8,158	8,150	8,186	7,961	8,182	8,218
Total Liabilities & Equity	12,283	12,348	11,967	11,370	11,749	11,789
Total Debt	765	735	692	582	837	889
Net Cash (Debt)	2,441	2,629	2,569	1,865	1,654	1,252
Net Cash Growth	-1.89%	2.34%	37.75%	12.76%	32.11%	135.25%
Net Cash Per Share	0.90	0.97	0.95	0.69	0.61	0.46
Filing Date Shares Outstanding	2,709	2,709	2,708	2,707	2,707	2,714
Total Common Shares Outstanding	2,709	2,709	2,708	2,707	2,707	2,714
Working Capital	4,055	3,984	4,389	3,912	3,862	3,511
Book Value Per Share	3.01	3.01	3.02	2.94	3.02	3.02
Tangible Book Value	4,799	4,796	4,914	4,686	4,585	4,217
Tangible Book Value Per Share	1.77	1.77	1.81	1.73	1.69	1.55
Land	10	10	11	11	11	11
Buildings	414	415	424	422	455	447
Machinery	1,332	1,309	1,298	1,243	1,222	1,187
Construction In Progress	9	7	13	5	17	43

Updated Jan 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.